Scilex Holding Company's subsidiaries, ACEA Therapeutics and ACEA Pharma, have agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings Limited for $1 billion. In exchange, ACEA Therapeutics will receive 100 million new shares of Phoenix Asia at $10 each. Post-acquisition, Phoenix Asia will be renamed ACEA Pharma, Inc. and is expected to list on Nasdaq by the end of Q2 2026. ACEA Therapeutics will hold approximately 82% ownership of the new entity, pending regulatory approvals.
A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...
Eversource has been recognized on TIME's list of America's Best Companies for 2026, highlighting its strong commitment to employee satisfaction, operational excellence, and sustainability. The ranking is based on surveys of over 217,000 employees and...
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2036, fueled by rising cancer incidence and the introduction of novel immunotherapies and targeted treatments....
Poolside has released Laguna S 2.1, a 118-billion-parameter open-weight AI model designed for agentic coding that matches or outperforms much larger models. It is compact enough to run on a single NVIDIA DGX Spark desktop and is available under an op...
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following a significant stock price drop. The decline occurred after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opi...
